Vimarsana
Biggest News Aggregation in the World

Page 49 - Accessed March News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Accessed March. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Accessed March Today - Breaking & Trending Today

Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients, Underscoring Best-in-Class Potential - Vimarsana News

Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients, Underscoring Best-in-Class Potential

/PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) reported positive topline results from a...

Novo Nordisk receives FDA approval of higher-dose Ozempic® 2 mg providing increased glycemic control for adults with type 2 diabetes - Vimarsana News

Novo Nordisk receives FDA approval of higher-dose Ozempic® 2 mg providing increased glycemic control for adults with type 2 diabetes

Ozempic® demonstrated 2.1% blood sugar reduction and also weight loss in adults with type 2 diabetes with new 2 mg dose1PLAINSBORO, N.J., March 28...

FDA Rejects Sintilimab Combo for First-Line Treatment of Nonsquamous NSCLC - Vimarsana News

FDA Rejects Sintilimab Combo for First-Line Treatment of Nonsquamous NSCLC

The FDA issued a complete response letter for sintilimab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of nonsquamous NSCLC.

Verastem Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress - Vimarsana News

Verastem Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress

Press release content from Business Wire. The AP news staff was not involved in its creation.

Source: apnews.com
Seqirus Receives Health Canada Approval for Expanded Age Indication of Its Cell-Based Quadrivalent Influenza Vaccine for People as Young as Six Months - Vimarsana News

Seqirus Receives Health Canada Approval for Expanded Age Indication of Its Cell-Based Quadrivalent Influenza Vaccine for People as Young as Six Months

/CNW/ -- Seqirus, a global leader in influenza prevention, announced today that it has received Health Canada approval of FLUCELVAX® QUAD (Influenza Vaccine),...